CLAIMS

1. Use of a) one or more antiretroviral agents selected from the group consisting of a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a nucleoside reverse transcriptase inhibitor (NRTI) and b) N-carbamimidoyl-5-(1-methylpyrazol-4-yl)naphthalene-2-carboxamide or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating HIV-1 infection and increasing the number of NK cells compared to the one or more antiretroviral agents alone.

2. The use according to claim 1, wherein administration of the combination increases the level of IL-21 in plasma compared to administration of the one or more antiretroviral agents alone.

3. The use according to claim 1, wherein administration of the combination increases the number of CD4+ T cells compared to administration of the one or more antiretroviral agents alone.

4. The use according to claim 1, wherein administration of the combination increases the number of CD8+ T cells compared to administration of the one or more antiretroviral agents alone.

5. The use according to claim 1, wherein administration of the combination reduces the level of sCD163 in plasma compared to administration of the one or more antiretroviral agents alone.

6. The use according to claim 1, wherein administration of the combination reduces downregulation of CD28 expression on CD4+ T cells infected with HIV-1 compared to administration of the one or more antiretroviral agents alone.

7. The use according to claim 1, wherein administration of the combination reduces downregulation of CCR7 expression on CD4+ T cells infected with HIV-1 compared to administration of the one or more antiretroviral agents alone.

8. The use according to claim 1, wherein administration of the combination reduces downregulation of CD80 expression on monocyte-derived macrophages infected with HIV-1 compared to administration of the one or more antiretroviral agents alone.

9. The use according to claim 1, wherein administration of the combination reduces downregulation of CD86 expression on monocyte-derived macrophages infected with HIV-1 compared to administration of the one or more antiretroviral agents alone.

10. The use according to claim 1, wherein the NNRTI is efavirenz

11. The use according to claim 1, wherein the NRTI is emtricitabine or tenofovir disoproxil fumarate (tenofovir DF).

12. The use according to claim 1 wherein the one or more the antiretroviral agents comprise efavirenz, emtricitabine and tenofovir DF.